Hashidate Hiroyuki, Kamimura Mikio, Ikegami Shota, Mukaiyama Keijiro, Uchiyama Shigeharu, Nakamura Yukio, Kato Hiroyuki
Department of Orthopedic Surgery, Shinshu University , Matsumoto , Japan and.
Endocr Res. 2015;40(3):172-6. doi: 10.3109/07435800.2014.982328. Epub 2014 Dec 23.
The present study measured changes in plasma pentosidine and bone turnover markers in elderly patients with osteoporosis treated using bisphosphonate. The relationship between pentosidine and bone turnover markers and bone mineral density (BMD) was investigated. This study consisted of post-menopausal osteoporotic women who could be treated using bisphosphonate for 3 years were included in the present analysis. The study population consisted of 58 cases, all women, ranging in age from 53 to 86 years (mean, 67.1 years). Bisphosphonate treatment significantly increased BMD of the lumbar spine to 0.914 ± 0.141 g/cm(2) and BMD of the femoral neck to 0.708 ± 0.086 g/cm(2) after 3 years (p < 0.001 versus baseline). The mean BAP level was 27.3 ± 8.3 U/L in patients at baseline. After bisphosphonate treatment, BAP significantly decreased to 18.1 ± 7.2 U/L at 3 years (p < 0.001). Urinary NTX also decreased after bisphosphonate treatment. After 3 years of treatment, urinary NTX significantly decreased from 50.0 ± 19.0 nmol BCE/mmol Cr to 24.6 ± 10.2 nmol BCE/mmol Cr at 3 years (p < 0.001). Serum pentosidine levels were 0.0413 ± 0.0094 μg/mL at baseline and 0.0413 ± 0.0122 μg/mL after 3 years. They were not significantly changed by bisphosphonate treatment. Serum pentosidine levels were not changed by treatment with bisphosphonates. Thus, serum pentosidine may not be suitable as a marker of bone quality after 3 years of bisphosphonate treatment.
本研究测量了使用双膦酸盐治疗的老年骨质疏松患者血浆戊糖苷和骨转换标志物的变化。研究了戊糖苷与骨转换标志物及骨密度（BMD）之间的关系。本分析纳入了可使用双膦酸盐治疗3年的绝经后骨质疏松女性。研究人群包括58例女性，年龄在53至86岁之间（平均67.1岁）。3年后，双膦酸盐治疗使腰椎骨密度显著增加至0.914±0.141g/cm²，股骨颈骨密度增加至0.708±0.086g/cm²（与基线相比，p<0.001）。患者基线时平均骨碱性磷酸酶（BAP）水平为27.3±8.3U/L。双膦酸盐治疗后，3年时BAP显著降至18.1±7.2U/L（p<0.001）。双膦酸盐治疗后尿I型胶原交联N-末端肽（NTX）也降低。治疗3年后，尿NTX从50.0±19.0nmol BCE/mmol Cr显著降至24.6±10.2nmol BCE/mmol Cr（p<0.001）。血清戊糖苷水平在基线时为0.0413±0.0094μg/mL，3年后为0.0413±0.0122μg/mL。双膦酸盐治疗未使其发生显著变化。双膦酸盐治疗未改变血清戊糖苷水平。因此，双膦酸盐治疗3年后，血清戊糖苷可能不适宜作为骨质量的标志物。
